TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
Business Wire•29/09/2026•16:01 ET
0
Key Highlights
- ➤China grants TriLink (MRVI) second CleanCap patent, broadening regional IP protection
- ➤New patent covers CleanCap cap analog compounds themselves and mRNA pharmaceutical compositions
- ➤Patent extends protection beyond synthesis methods to molecules, RNA, cells, and drug products
- ➤CleanCap IP portfolio spans United States, European Union, Australia, Japan, Korea, Hong Kong, Canada, and China
- ➤TriLink offers licensing opportunities for mRNA products using CleanCap technology
Expert Statements
Bernd Brust, Chief Executive Officer of Maravai LifeSciences
“This new Chinese patent represents an important expansion of our CleanCap® intellectual property position. Where our first Chinese patent covers the methods of using CleanCap® to produce capped RNA, this new patent covers the cap analog compounds themselves and the pharmaceutical compositions that incorporate them.”
Chanfeng Zhao, Chief Scientific Officer of TriLink BioTechnologies
“The granted claims in this patent reflect the deep scientific rigor our team applied in developing the CleanCap® platform. We remain committed to advancing the science of mRNA capping, and we are proud that CleanCap® continues to be the technology of choice for researchers and developers working on some of the most important medicines of our time.”
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
New Patent Protects the CleanCap® Cap Analog Compounds Themselves and mRNA-Based Pharmaceutical Compositions — Extending Beyond Method Claims to Cover the Molecules at the Heart of Modern mRNA Medicines
Get started
Create a free account to read the full story.